Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-27
2005-12-27
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S009100, C530S350000
Reexamination Certificate
active
06979673
ABSTRACT:
Compositions containing cyclophilin B, mutants of cyclophilin B or inhibitors of cyclophilin B and methods of using these compositions to modulate somatolactogenic function are provided.
REFERENCES:
Denys et al., 1998. Transplantation 65(8):p1076-1084 (see 1076).
Price et al., 1991. Proc. Natl. Acad. vol. 88. pp. 1903-1907 (see abstract).
Denys et al. 1998, Transplantation, vol. 65(8): 1076-1084.
Price et al. 1991, Proc. Natl. Acad. vol. 88: 1903-1907.
Gura 1997, Science vol. 278, No. 7, pp. 1041-1042.
Allain et al. 1996, Biochem. J. vol. 317: pp. 565-570.
Allain et al., “Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies”,J. Immunol. Meth.1995 178:113-120.
Bazan J.F., “Haemopoietic receptors and helical cytokines”,Immunol. Today1990 11: 350-354.
Bram et al., “Identification of the Immunophilins Capaboe of Mediating Inhibition of Signal Transduction by Cyclosporin A and FK506: Roles of Calcineurin Binding and cellular Location”,Mol. Cell Biol.1993 13:4769.
Campbell et al., “Activation of JAK2 tyrosine kinase by prolactin receptors in NB2cells and mouse manary gland explants”,Proc. Natl Acad. Sci. USA1994 91:5232-5236.
Clevenger et al., “Prolactin Induces Rapid Phosphorylation and Activation of Prolactin Receptor-associated RAF-1 Kinase in a T-cell Line”,J. Biol. Chem.1994 269:5559-5565.
Clevenger et al., “The Protein Tyrosine Kinase p59fynIs Associated with Prolactin (PRL) Receptor and Is Activated by PRL Stimulation of T-Lymphocytes”,Mol. Endocrinol.1994 8:674-681.
Clevenger et al., “Vav Is Necessary for Prolactin-stimulated Proliferation and Is translocated into the Nucleus of a T-cell Line”,J. Biol. Chem.1995 270:13246-13253.
Clevenger et al., “Interleukin-2 Driven Nuclear Translocation of Prolactin in Cloned T-Lymphocytes”,Endocrinology1990 127:3151-3159.
Clevenger et al., “Requirement of Nuclear Prolactin for Interleukin-2-Stimulated Proliferation of T Lymphocytes”,Science1991 253:77-79.
Clevenger et al., “Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin”,Proc. Natl Acad. Sci. USA1990 87:6460-6464.
Clevenger et al., “Prolactin receptor signal transduction in cells of the immune system”,Journal of Endocrinology1998 157:187-197.
Clevenger C.V. and Plank T.L.J., “Prolactin as an Autocrine/Paracrine Factor in Breast Tissue”,J. Mammary Gland Biol. Neoplasia1997 2:59-68.
Clevenger et al., “Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma”,Am. J. Pathol.1995 146:1-11.
Dardenne et al., “Prolactin Receptor Expression in Human Hematopoietic Tissues Analyzed by Flow Cytofluorometry”,Endocrinology1994 134:2108-2114.
DiMattia et al., “A Human B-Lymphoblastoid Cell Line Produces Prolactin”,Endocrinology1986 122:2508-2517.
Fields et al., “Detection of Prolactin messenger RNA in Mammary and Other Normal and Neoplastic Tissues by Polymerase Chain Reaction”,Lab. Invest.1993 68:354-360.
Friedman et al., “Two Cytoplasmic Candidates for Immunophilin Action Are Revealed by Affinity for a New Cyclophilin: One in the Presence and One in the Absense of CsA”,Cell1991 66:799-806.
Gala, R.R.PRL and GH Regulation of Immune Function,“Prolactin and Growth Hormone in the Regulation of the Immune System”, 1991 198:513-527.
Gellersen et al., “Nonpiuitary Human Prolactin gene Transcription is Independent of Pit-1 and Differentially Controlled in Lymphocytes and in Endometrial Stroma”,Mol. Endocrinol.1994 8:356-373.
Ginsburg et al., “Prolactin Synthesis and Secretion by Human Breast Cancer Cells”,Cancer Res.1995 55:2591-2595.
Gout et al., “Prolactin-stimulated Growth of Cell Cultures Established from Malignant NB Rat Lymphomas1”,Cancer Res.1980 40:2433-2436.
Harada et al., “Absence of the Type I IFN System in EC Cells:Transcriptional Activator (IRF-1) and Repressor (IRF-2) Genes Are Developmentally Regulated”,Cell1990 63:303-312.
Kooijman et al., “Prolactin, Growth Hormone, and Insulin-like Growth Factor-I in the Immune System”,Adv. Immunol.1996 63:377-454.
Kronke et al., “Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription”,Proc. Natl Acad. Sci. USA1984 81:5214-5218.
Liu et al., “Calcineurin Is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes”,Cell1991 55:807.
Malarkey et al., “Physiological Concentrations of Prolactin Can Promote the Growth of Human Breast Tumor Cells in Culture”,J. Clin. Endocrinol. Metab.1983 56:673-677.
Mariller et al., “Evidence that human milk isolated cyclophilin B corresponds to a truncated form”,Biochem. Biophys. Acta1996 1293:31-38.
McCaffrey et al., “NF—ATp, a T Lymphocyte DNA-binding Protein That Is a Target for Calcineurin and Immunosuppressive Drugs”,J. Biol. Chem.1993 268:374.
Mershon et al., “Prolactin Is a Local growth Factor in Rat Mammary Tumors”,Endocrinology1995 136:3619-3623.
Mertani et al., “Cellular Expression of Growth Hormone and Prolactin Receptors in Human Breast Disorders”,Int. J. Cancer1998 79:202-211.
Nicoll C.S., “Physiological actions of prolactin”,Handbook of Physiology;Section 7:Endocrinology,pp. 253-292, Washington, D.C.: American Physiology Society 1974.
Ormandy et al., “Coexpression and Cross-Regulation of the Prolactin Receptor and Sex Steriod Hormone Receptors in Breast Cancer”,J. Clin. Endocrinol. Metab.1997 82:3692-3699.
Pellegrini et al., “Expression of Prolactin and Its Receptor in Human Lymphoid Cells”,Mol, Endocrinol.1992 6:1023-1031.
Perrot-Applanat et al., “Internalization of prolactin receptor and prolactin in transfected cells does not involve nuclear translocation”,J. Cell Sci.1997 110:1123-1132.
Price et al., “Human cyclophilin B: A second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence”,Proc. Natl Acad. Sci. USA1991 88:1903-1907.
Prystowski M.B. and Clevenger C.V., “Prolactin as a Second Messenger for Interleukin 2”,Immunomethods1994 5:49-55.
Rao et al., “Nuclear Translocation of Prolactin:Collaboration of Tyrosine Kinase and Protein Kinase C Activation in Rat Nb2 Node Lymphoma Cells”,Cell Physiol.1995 163:266-276.
Resch K. and Szamel M., “Molecular Mechanisms of the Immunosuppressive Action of Cyclosporin A”,Int. J. Immunopharmac.1997 19:579.
Rühlmann A. and Nordheim A., “Effects of the Immunosuppressive Drugs CsA and FK506 on Intracellular Signalling and Gene Regulation”,Immunobiol.1997 198:192-206.
Streblow et al., “Cyclophilin A Modulates Processing of Human Immunodeficiency virus Type 1 p55GagMechanism for Antiviral Effects of Cyclosporin A”,Virology1998 245:197-202.
Taylor et al., “Structures of Cyclophilin-Ligand Complexes”,Prog. Biophys. Molec. Biol.1997 67:155-181.
Weigent D.A., “Immunoregulatory Properties of Growth Hormone and Prolactin”,Pharmacol. Ther.1996 69:237-257.
Welsch C.W. and Nagasawa H., “Prolactin and Murine Mammary Tumorigenesis:A Review”, Cancer Res. 1977 37:951-963.
Welsch C.W., “Host Factors Affecting the Growth of Carcinogen-induced Rat Mammary Carcinomas:A Review and Tribute to Charles Brenton Huggins”,Cancer Res.1985 45:3415-3443.
Yu-Lee L.Y., “Molecular Actions of Prolactin in the Immune System (44111)”,Prolactin and IRF-1 In Immune Regulation1997 215:35-51.
Clevenger Charles V.
Rycyzyn Michael A.
Chism B. Dell
Licata & Tyrrell P.C.
Tate Christopher R.
Trustees of the University of Pennsylvania
LandOfFree
Method and compositions for modulating somatolactogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for modulating somatolactogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for modulating somatolactogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3471418